FDA Event

ID TICKER DATE Notes To Know Time Broker Rating
1 UROV 05/05/2019 Urovant Sciences to present theapies at the American Urological Associatiomeeting in Chicago 2:10 pm ET Cowen Outperform $25 PT JPM Overweight $24 PT SuntTrust Buy $23 PT
2 NVS 05/05/2019 Phase 3 commencement of dosing announced April 25, 2018.Data at AAN May 5, 2019, 11:30 AM.Completion 2021. Credit Suisse Outperform $66 PT Guggenheim Buy $86 PT
3 PGNX 06/05/2019 Phase 2/3 data to be presented at AUA May 6, 2019.Phase 3 data due early 2020. Needham Buy $10 PT
4 MNOV 06/05/2019 Phase 2b top-line data released October 28, 2017. Primary endpoint met.Additional data to be presented at AAN meeting May 6, 2019 at 2:06 PM ET. B.Riley Buy $22 PT
5 RARX 07/05/2019 Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. Raymond James Outperform $49 PT Stifel Buy $48 PT
6 GWPH 07/05/2019 Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. Oppenheimer Perform $162 PT Piper Overweight $185 PT
7 BHVN 07/05/2019 Phase 3 data to be presented at AAN in late-breaker May 7, 2019. Leerink Outperform $67 PT Oppenheimer Outperform $70 PT Cannaccord Buy $80 PT
8 DRRX 07/05/2019 Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. To report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its earnings after the close
9 BIIB 07/05/2019 Phase 1/2 data to be presented at AAN in late-breaker May 7, 2019.Phase 3 data due 2H 2020. Pipper Overweight $280 PT RBC Sector Perform $234 PT Cannaccord Neutral $275 PT
10 OVID 07/05/2019 Phase 1/2 data to be presented at AAN in late-breaker May 7,2019.Phase 3 data due 2H 2020. Cantor Overweight $7.00 PT Pipper Overweight $14.00PT
11 PTCT 07/05/2019 Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. Bernstein Outperform $47 PT
12 CATB 09/05/2019 Phase 3 data due 2Q 2020.Phase 1/2 data to be presented at AAN May 9,2019.
13 QURE 10/05/2019 Phase 2b 26-week follow-up data to be presented at HTRS May 10,2019. Piper Overweight $80 PT
14 SESN 13/05/2019 PDUFA date for sBLA May 13,2019.
15 REGN 13/05/2019 PDUFA date for sBLA May 13, 2019. Jefferies Hold $343 PT
16 AMGN 15/05/2019 Phase 1 data due at ASCO June 3,2019, 9am. BMO Outperform $229 Jefferies Buy $230
17 MRTX 17/05/2019 Phase 1/2 update due 2H 2019.On watch for potential impact from release of ASCO abstract for AMGN 510 on May 15,2019. DA Davidson Neutral $22
18 ACHN 17/05/2019 Phase 2 interim data due May 17,2019. Barclays Underweight $2.50
19 MDCO 18/05/2019 Phase 2 open-label data to be presented at National Lipid Association Scientific Sessions on May 18, 2019. Goldman Buy $54
20 BMY 20/05/2019 The FDA determined at that time, that the submission of this new information constituted a major amendment to the Sbla and extended the review. JPM Overweight $59 PT Barclays Overweight $55 PT
21 ATHX 20/05/2019 Phase 2a data released January 23,2019.Data to be presented at ATS, May 20,2019.Phase 2 ONE-BRIDGE commencement of enrolment announced.
22 LLY 20/05/2019 Phase 2 data due at DDW meeting 18-21 May,2019 BMO Capital Outperform $133 PT Edward Jones Buy $116 PT
23 PIRS 22/05/2019 Phase 1 initial data due at ATS meeting May 22,2019 1:30pm.
24 INCY 24/05/2019 PDUFA date under priority review extended by three months to May 24,2019. Barclays Equaweight $82PT Stifel Hold $92PT
25 NVS 24/05/2019 PDUFA date under priority review extended by three months to May 24,2019. Guggenheim Buy $86 PT
26 CNCE 28/05/2019 Phase 1 data to be presented at ASCP May 28-31,2019. Stifel Buy $18 PT Mizuho Buy $23 PT

Leave a Reply

Your email address will not be published. Required fields are marked *